235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt

Rhea-AI Filing Summary

Vogt Frederick G reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. granted Interim CEO & General Counsel Frederick G. Vogt 235,000 restricted stock units (RSUs) on March 9, 2026. Each RSU represents a contingent right to receive one share of Iovance common stock.

Vesting depends on continued employment. One-third of the RSUs will vest on the one-year anniversary of the grant date. The remaining RSUs will then vest in eight equal quarterly installments over the following two years, starting with the first quarter after the first anniversary.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vogt Frederick G

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		235,000		(2)	(2)	Common stock	235,000	$0.00	235,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Frederick G. Vogt	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Frederick Vogt?

IOVANCE BIOTHERAPEUTICS reported that Interim CEO & General Counsel Frederick G. Vogt received a grant of 235,000 restricted stock units (RSUs) on March 9, 2026. Each RSU represents a contingent right to receive one share of the company’s common stock, subject to vesting conditions.

How do the 235,000 RSUs granted to IOVA’s Frederick Vogt vest?

The 235,000 RSUs granted to Frederick Vogt vest over three years. One-third vests on the one-year anniversary of the grant date, and the remaining two-thirds vest in eight equal quarterly installments over the next two years, assuming continued employment.

What does each RSU granted to IOVANCE’s Frederick Vogt represent?

Each RSU granted to Frederick Vogt represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. Actual share delivery depends on the RSUs vesting according to the three-year schedule and Vogt’s continued employment with the company on required vesting dates.

Is the Form 4 transaction for IOVA’s Frederick Vogt a purchase or a grant?

The Form 4 transaction for Frederick Vogt is a grant/award acquisition of 235,000 RSUs, coded “A” for grant. It is a compensation-related award, not an open-market share purchase or sale, and therefore does not reflect a discretionary market trade.

What role does Frederick Vogt hold at IOVANCE BIOTHERAPEUTICS (IOVA) in this Form 4?

In this Form 4, Frederick G. Vogt is identified as Interim CEO & General Counsel of IOVANCE BIOTHERAPEUTICS. The reported transaction reflects an equity-based compensation grant of 235,000 RSUs, aligning part of his compensation with the company’s common stock performance over time.